Moderna: Oddo still a buyer
(CercleFinance.com) - Oddo maintains its Outperform rating on the Moderna stock with a target price target of 297 dollars.
The analyst highlights the company's rich and diversified portfolio in rare diseases and notes the current progress of the rare disease platform, which he says could potentially be the second platform to bring a new mRNA to market after prophylactic vaccines.
Oddo also points to Moderna's ability to expand its portfolio beyond prophylactic vaccines. The first phase 2 results of mRNA-4157, its personalised cancer vaccine, are due to be announced in the last quarter of 2022 "and, if positive, should reassure investors in our view".
The presentation of Moderna was "very reassuring, demonstrating both the group's innovation and its ability not to be solely dependent on COVID-19," said Oddo, which maintains its Outperform rating.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The analyst highlights the company's rich and diversified portfolio in rare diseases and notes the current progress of the rare disease platform, which he says could potentially be the second platform to bring a new mRNA to market after prophylactic vaccines.
Oddo also points to Moderna's ability to expand its portfolio beyond prophylactic vaccines. The first phase 2 results of mRNA-4157, its personalised cancer vaccine, are due to be announced in the last quarter of 2022 "and, if positive, should reassure investors in our view".
The presentation of Moderna was "very reassuring, demonstrating both the group's innovation and its ability not to be solely dependent on COVID-19," said Oddo, which maintains its Outperform rating.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.